{"title":"Blinatumomab improves outcomes in adult MRD-negative BCP-ALL","authors":"Diana Romero","doi":"10.1038/s41571-024-00936-5","DOIUrl":null,"url":null,"abstract":"<p>Adults with B cell-precursor acute lymphoblastic leukaemia (BCP-ALL) negative for minimal residual disease (MRD) after induction chemotherapy have a superior prognosis relative to those with MRD<sup>+</sup> status, although many will eventually have disease relapse. Now, data from the phase III E1910 trial demonstrate that addition of the CD19 × CD3 bispecific T cell engager blinatumomab to consolidation chemotherapy improves overall survival (OS) in this setting.</p><p>Patients received standard-of-care induction chemotherapy. Those with an MRD<sup>–</sup> complete response (<0.01% leukaemic cells in bone marrow; 224 of 488 patients) were randomly allocated (1:1) to receive standard-of-care consolidation chemotherapy with or without blinatumomab, followed by standard maintenance therapy in both groups. OS in patients with MRD<sup>–</sup> disease was the primary end point.</p>","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":81.1000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-024-00936-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Adults with B cell-precursor acute lymphoblastic leukaemia (BCP-ALL) negative for minimal residual disease (MRD) after induction chemotherapy have a superior prognosis relative to those with MRD+ status, although many will eventually have disease relapse. Now, data from the phase III E1910 trial demonstrate that addition of the CD19 × CD3 bispecific T cell engager blinatumomab to consolidation chemotherapy improves overall survival (OS) in this setting.
Patients received standard-of-care induction chemotherapy. Those with an MRD– complete response (<0.01% leukaemic cells in bone marrow; 224 of 488 patients) were randomly allocated (1:1) to receive standard-of-care consolidation chemotherapy with or without blinatumomab, followed by standard maintenance therapy in both groups. OS in patients with MRD– disease was the primary end point.
期刊介绍:
Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.